SCHEMBL12430692

SCHEMBL12430692

COC(=O)c1cccc(Nc2nc(Nc3cc(C4CC4)[nH]n3)c3ccccc3n2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 4/20 0.64
PDK1 Q15118 1/20 0.57
ULK2 Q8IYT8 1/20 0.57
NTRK1 P04629 2/20 0.56
IGF1R P08069 2/20 0.56
PDE5A O76074 1/20 0.55
SRC P12931 3/20 0.54
GSK3B P49841 3/20 0.54
AURKB Q96GD4 1/20 0.54
NTRK3 Q16288 1/20 0.53
NTRK2 Q16620 1/20 0.53
AURKA O14965 1/20 0.52
PAK4 O96013 1/20 0.52
PAK1 Q13153 1/20 0.52
ABCG2 Q9UNQ0 2/20 0.52
ABCB1 P08183 1/20 0.52
KDM4E B2RXH2 1/20 0.51
MAPT P10636 1/20 0.51
CCNA2 P20248 1/20 0.51
CDK2 P24941 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31471747 0.91 ULK1 (0.72) ULK1PDK1ULK2NTRK1IGF1R
SCHEMBL12430693 0.91 ULK1 (0.68) ULK1PDK1ULK2NTRK1IGF1R
SCHEMBL7108312 0.85 ULK1 (0.68) ULK1PDK1ULK2NTRK1IGF1R
SCHEMBL12430667 0.85 ULK1 (0.86) ULK1PDK1ULK2NTRK1IGF1R
SCHEMBL31471779 0.85 ULK1 (0.86) ULK1PDK1ULK2NTRK1IGF1R
SCHEMBL22072049 0.84 ULK1 (0.72) ULK1PDK1ULK2NTRK1IGF1R
SCHEMBL12430668 0.84 ULK1 (0.72) ULK1PDK1ULK2NTRK1IGF1R
SCHEMBL2204849 0.84 PDE5A (0.55) ULK1PDE5ASRCGSK3BAURKA
SCHEMBL12430694 0.84 ULK1 (0.68) ULK1PDK1ULK2NTRK1IGF1R
SCHEMBL31471718 0.83 ULK1 (0.68) ULK1PDK1ULK2NTRK1IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, AURKC, AURKA ULK1 965/4885PDK1 268/4885ULK2 487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.